This hormone plays a crucial role in regulating appetite and blood sugar
Given the copper pathways implicated, users with pre-existing copper overload, Wilson disease, or severe liver disease may be at increased risk and should avoid use
By binding to GLP-1 receptors throughout the body, these medications enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety
Put differently: if you tried to anchor the dose on BPC-157 or TB-500 instead (which are usually run at higher standalone amounts), you would have to inject a much larger volume and would flood GHK-Cu far past its useful range
See How to Read a Janoshik COA , Vegan Peptides , and the Lab Results page
A recent in vivo study in healthy subjects showed that acute intravenous infusion of GLP-1 during a pancreatic clamp, in which insulin and glucagon levels were maintained at basal levels, caused a reduction in hepatic glucose production, suggesting a potential direct effect on gluconeogenesis [11]